Hologic shares remained relatively unmoved today on first-quarter results that fell shy of the Wall Street forecast.
HOLX's GYN Surgical unit, boosted by MyoSure, Fluent and Gynesonics, drives 10.2% revenue growth and is likely to lift ...
Hologic slips after a Q1 EPS and revenue miss, as gross margin fell 150 bps with Diagnostics weakness offset by strong GYN ...
Hologic, Inc. HOLX GYN Surgical is expected to have registered vital contributions from MyoSure and the Related fluid system, with an increasing contribution from its laparoscopic portfolio. Moreover, ...
Hologic HOLX is set to release first-quarter fiscal 2026 results on Jan. 29, after the closing bell. The Zacks Consensus ...
Hologic has been outperforming peers but underperforming the broader medical device sector, with shares up about 5% since my last analysis. Fiscal Q3 results showed consistent beats in Diagnostics, ...
On Monday, Hologic Inc (NASDAQ:HOLX) agreed to acquire Gynesonics, Inc. for approximately $350 million. Gynesonics is a privately held medical device company that develops minimally invasive solutions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results